Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial.

Journal of Korean Medical Science
Dae Won ParkMin Ja Kim

Abstract

The efficacy and safety of ertapenem, 1 g once daily, were compared with that of ceftriaxone, 2 g once daily, for the treatment of adults with acute pyelonephritis (APN) and complicated urinary tract infections (cUTIs) in a prospective, multicenter, double-blinded, randomized study. After ≥ 3 days of parenteral study therapy, patients could be switched to an oral agent. Of 271 patients who were initially stratified by APN (n = 210) or other cUTIs (n = 61), 66 (48.9%) in the ertapenem group and 71 (52.2%) in the ceftriaxone group were microbiologically evaluable. The mean duration of parenteral and total therapy, respectively, was 5.6 and 13.8 days for ertapenem and 5.8 and 13.8 days for ceftriaxone. The most common pathogen was Escherichia coli. At the primary efficacy endpoint 5-9 days after treatment, 58 (87.9%) patients in the ertapenem group and 63 (88.7%) in the ceftriaxone had a favorable microbiological response. When compared by stratum and severity, the outcomes in the two groups were equivalent. The frequency and severity of drug-related adverse events were generally similar in both treatment groups. The results indicate that ertapenem is highly effective and safe for the treatment of APN and cUTIs.

References

Oct 6, 1997·Infectious Disease Clinics of North America·T M Hooton, W E Stamm
Dec 10, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J W WarrenW E Stamm
Dec 19, 2000·Annals of Epidemiology·B FoxmanJ D Sobel
Apr 11, 2001·International Journal of Antimicrobial Agents·A R RonaldV Andriole
Sep 15, 2001·Antimicrobial Agents and Chemotherapy·D M LivermoreM Warner
Dec 26, 2001·European Urology·K G NaberUNKNOWN Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU)
Mar 27, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Guillermo Ortiz-RuizUNKNOWN Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group
May 17, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Donald R GrahamRichard Gesser
May 1, 2004·The Journal of Antimicrobial Chemotherapy·A AlhambraJ I Alós
May 20, 2004·The Journal of Antimicrobial Chemotherapy·Hedy TepplerRobin Isaacs
Nov 4, 2004·American Journal of Epidemiology·Moran KiBetsy Foxman
Jul 11, 2006·International Journal of Antimicrobial Agents·Tetsuro Muratani, Tetsuro Matsumoto
Feb 15, 2008·The Journal of Antimicrobial Chemotherapy·Elizabeth M Johnson
Dec 14, 2007·The Journal of Antimicrobial Chemotherapy·Marie-Hélène Nicolas-ChanoineJames R Johnson
Dec 27, 2007·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·L E Nicolle, UNKNOWN AMMI Canada Guidelines Committee*
May 17, 2008·Diagnostic Microbiology and Infectious Disease·Kwan Soo KoNam Yong Lee
Oct 10, 2008·Academic Medicine : Journal of the Association of American Medical Colleges·Rachel YudkowskyMihaela Popescu
Oct 24, 2008·Current Infectious Disease Reports·Paola Lichtenberger, Thomas M Hooton

❮ Previous
Next ❯

Citations

May 29, 2016·International Journal of Antimicrobial Agents·Michael P VeveSusan L Davis
Aug 14, 2013·Antimicrobial Agents and Chemotherapy·Krishan P SinghLinda M Mundy
Nov 18, 2017·International Journal of Clinical Pharmacy·Samantha S WangWilliam R Judd

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.